Metropolitan Life Insurance Company (MetLife)’s Repros Therapeutics Inc. RPRX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-21,089	Closed	-$181K	–	2753
2015 Q1	$181K	Hold	21,089	–	–	﹤0.01%	2107
2014 Q4	$210K	Buy	21,089 +1,270	+6%	+$10.8K	﹤0.01%	2386
2014 Q3	$196K	Hold	19,819	–	–	﹤0.01%	2383
2014 Q2	$343K	Hold	19,819	–	–	﹤0.01%	2101
2014 Q1	$352K	Hold	19,819	–	–	﹤0.01%	2046
2013 Q4	$363K	Hold	19,819	–	–	﹤0.01%	2037
2013 Q3	$531K	Buy	19,819 +3,766	+23%	+$80.7K	﹤0.01%	1719
2013 Q2	$296K	Buy	+16,053	New	+$284K	﹤0.01%	2057

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

GAI

General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCM

Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RPRX Position: Q2 2015 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 21,089 shares — an estimated $181K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RPRX in Q2 2013 and held it in 8 quarters. The position peaked at $531K in Q3 2013. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

Metropolitan Life Insurance Company (MetLife) reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 21,089 Repros Therapeutics Inc. shares in Q2 2015, an estimated $181K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 8 quarters.
Metropolitan Life Insurance Company (MetLife)'s Repros Therapeutics Inc. position peaked at $531K in Q3 2013.
64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2015, filed 17 Aug 2015.